Indication
CERINIB (Ceritinib) 150mg is approved for treating metastatic or inoperable non-small cell lung cancer (NSCLC) with specific genetic mutations (ALK-positive NSCLC).

Pharmacology
Ceritinib is a tyrosine kinase inhibitor that targets proteins like ALK, crucial for cancer cell survival and growth, thereby impeding tumor progression.

Dosage and Administration
Typically, CERINIB is taken orally at 450mg once daily with food. Dosage adjustments may be needed based on individual response and tolerance.

Interactions

CERINIB may interact with various drugs, including other anti-cancer medications, certain antibiotics, antifungals, and drugs affecting liver enzymes. Patients should inform their healthcare provider about all medications they’re taking.

Side Effects
Common side effects of CERINIB include gastrointestinal issues (like diarrhea, nausea, vomiting), fatigue, increased liver enzymes, and peripheral edema. Serious effects may involve lung disease, liver problems, bradycardia, and high blood sugar.

Precautions and Warnings
Patients should undergo regular monitoring of liver and cardiac functions during CERINIB treatment, especially those with a history of heart, liver, or lung issues.
– Effective contraception is advised for women of childbearing age due to potential fetal harm. Breastfeeding should be avoided while on CERINIB.

Overdose Effects
Overdose may worsen side effects, such as gastrointestinal symptoms, liver issues, and cardiac complications. Managing overdose usually involves supportive care and close monitoring of vital signs.

.